FDA Warns Boston’s TEI Biosciences Over ‘Systemic’ Quality Failures

The GMP Letter
The FDA issued a warning letter to TEI Biosciences’ for “systemic” quality failures the agency found during an Oct. 9 to Nov. 2, 2018, inspection of its Boston, Mass., facility.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00